TAS2R31

Across TCGA pan-cancer cohorts, TAS2R31 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAS2R31 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TAS2R31 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAS2R31 expression acts as an unfavorable survival marker.

BRCA, SKCM, and BLCA are the cancer types where TAS2R31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.773	0.950	<.001	30	view →
SKCM	OS	Median	All	0.166	0.785	<.001	28	view →
BLCA	OS	Median	III,IV	0.251	0.688	<.001	18	view →
COAD	OS	Median	All	0.001	0.871	<.001	16	view →
KIRP	DFS	Median	All	0.178	0.867	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAS2R31–BRCA (DFS)

Open the BRCA breakdown →